Health Care & Life Sciences » Biotechnology | Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Intercept Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
SPDR S&P Biotech ETF
963,041
3.26%
2,478
1.84%
09/06/2018
Fidelity Select Biotechnology Portfolio
806,025
2.73%
800
0.98%
07/31/2018
First Trust NYSE Arca Biotechnology Index Fund
789,041
2.67%
0
3.8%
09/05/2018
Vanguard Small Cap Index Fund
558,263
1.89%
7,996
0.06%
07/31/2018
Vanguard Total Stock Market Index Fund
555,172
1.88%
672
0.01%
07/31/2018
BB Biotech AG
545,719
1.85%
60,000
1.47%
03/31/2018
iShares Russell 2000 ETF
463,546
1.57%
-249
0.11%
09/06/2018
Fidelity OTC Portfolio
417,919
1.41%
0
0.21%
07/31/2018
JPMorgan Growth Advantage Fund
383,600
1.3%
2,700
0.45%
07/31/2018
Fidelity Select Health Care Portfolio
367,400
1.24%
600
0.54%
07/31/2018

About Intercept Pharmaceuticals

View Profile
Address
10 Hudson Yards
New York New York 10001
United States
Employees -
Website http://www.interceptpharma.com
Updated 07/08/2019
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.